---
document_datetime: 2025-09-25 12:23:06
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/padcev-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: padcev-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6607043
conversion_datetime: 2025-12-25 05:44:00.044209
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Padcev

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number         | Scope   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------------|---------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| PSUR / EMA/PSUR/0000257872 | - -     | 24/07/2025                          | 17/09/2025                                  | SmPC and PL                      | Variation |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | In view of available data on pneumonia from clinical trials and from spontaneous reports including in some cases a close temporal relationship and a positive de-challenge the PRAC considers a causal relationship between enfortumab vedotin and pneumonia is at least a reasonable possibility. The PRAC concluded that the product information of products containing enfortumab vedotin should be amended accordingly. In view of available data on thrombocytopenia from clinical trials and from spontaneous reports including in some cases a close temporal relationship and a positive de-challenge the PRAC considers a causal relationship between enfortumab vedotin and thrombocytopenia is at least a reasonable possibility. The PRAC concluded that the product information of products containing enfortumab vedotin should be amended   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000256819 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z - To update NI-PASS (7465-PV- 0002) category 3 study milestone from 'Q4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 05/06/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | 2024' to 'Q3 2025' after receipt of the CHMP conclusion for protocol amendment EMEA/H/C/005392/MEA/003.2. Furthermore, some minor editorial corrections are included.                                                                                                                                                                                                                                                                                                   |            |     |                   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IB /                   | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation - Accepted | 13/05/2025 | N/A | EMA/VR/0000265102 |
| Variation type IB / EMA/VR/0000248972 | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                                                       | 03/03/2025 | N/A |                   |